EGFR and neoplasm: In conclusion, these pre-clinical data show not only the key role of Src kinase family in the acquisition and maintenance of tumor resistance to EGFR inhibitors, especially in lung cancer, but also help drive which approaches to prioritize for novel clinical therapeutic combinations aimed to overcome the effects of such resistance.